TIMI is proud to celebrate our 40th anniversary! Since 1984, we've been dedicated to advancing the knowledge and care of patients suffering from cardiovascular disease and its risk factors. View the 40th anniversary edition of the TIMI book, now online.
https://t.co/NXuasBCjV4
AF pts in 4 RCTs from COMBINE-AF show #DOACs had a favorable net clinical benefit over warfarin using a patient-weighted composite clinical outcome. Out now in @NEJMEvidence@rgiugliano
https://t.co/mQoFdxBGkR
One of my favorite projects at TIMI.
While exploratory, our findings support the concept that lowering LDL-C through PCSK9i may prevent the formation and progression of arterial aneurysms, including AAA.
Now in @CircAHA@PrakritiGaba@marstonMD@BrianBergmark@TIMIStudyGroup
Delighted to host Christian Ruff @TIMIStudyGroup@nyulangone for Cardioloyy Grand Rounds.
The current and future state of Factor XI inhibition for #afib
In #VESALIUS-CV, Lp(a) was associated with risk of major coronary events and helped identify those with larger absolute benefit from #evolocumab. LBCT presentation at @EASCongress and online now at @CircAHA@rgiugliano@EBohula
https://t.co/Q9wwsOPZ81
Congratulations to Senior TIMI Biostatistician Andrea Bellavia, PhD, who was awarded the Teaching Citation Award from the Harvard T.H. Chan School of Public Health for excellence as a Lecturer in Biostatistics! @HarvardChanSPH
Similar 10-year survival following PCI vs CABG for left main disease in combined analysis of SYNTAX, PRECOMBAT, NOBLE, and EXCEL trials. @BrianBergmark#EuroPCR
Vasoactive treatment in cardiogenic shock varies widely across CICUs, driven by patient-level factors and institutional practice patterns @TIMIStudyGroup@DrRobRoswell@ICUDocAP@TIMIStudyGroup https://t.co/JiluwN0PIv
Listen again to the TIMI Talks podcast episode with legendary cardiologist and TIMI Study Group founder Dr. Eugene Braunwald, where he discussed his illustrious career and the beginnings of TIMI. @ddbergMD
https://t.co/0nutLNGTwC
While he touched many lives, we at TIMI were truly blessed to directly work with and learn from him over treasured decades. We will deeply miss him, but take comfort in knowing that we will carry forward his legacy and continue his lifelong mission to advance cardiovascular care.
We are deeply saddened to have lost our founding chairman and the father of modern academic cardiology, Dr. Eugene Braunwald, who founded the TIMI Study Group in 1984, and with that vision profoundly shaped the practice of cardiovascular medicine across the world.
More than 40 years, 80 clinical trials, and 450,000 trial participants later, we are proud that the TIMI Study Group has impacted almost every facet of cardiovascular care. Dr. Braunwald’s intellectual rigor and zeal for discovery were legendary.
Simulation from large US cohort of ACS pts shows triple lipid Rx (↑-intensity statin, ezetimibe, PCSK9i) before discharge would achieve LDL <55 mg/dL in 99.8% & <40 mg/dL in 98.7% of pts, w/a 36% further ↓ in CV events @ 5 yrs c/w ↑-intensity statin monotherapy @rgiugliano